Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Our Cardiovascular Commitment

“We strive to help patients with cardiovascular diseases by developing innovative treatments. Since 2002 our cardiovascular treatments have improved outcomes of over 40 million* patients across Europe.”

We are the pioneer behind leading pharmaceuticals such as

  • Adrenalin (an adrenal cortex hormone agent that became the first blockbuster medicine of the 20th century) 
  • Pravastatin (a globally groundbreaking anti-hyperlipidemic agent)

Our current cardiovascular portfolio includes products for

  • Atrial fibrillation
  • Thrombotic disorders
  • Hypertension
  • Dyslipidaemia
  • Hypercholestrolaemia


*40 million patients treated with olmesartan and its combinations, prasugrel, edoxaban, pravastatin in selected countries